Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants With Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
ASP1012
Pembrolizumab
Locations
8
United States
The Angeles Clinic and Research Institute
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Emory Winship Cancer Institute
Atlanta, Georgia, United States
University of Iowa Hospitals
Iowa City, Iowa, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
May 15, 2024
Primary Completion Date
September 10, 2025
Completion Date
September 10, 2025
Last Updated
November 4, 2025
NCT06898450
NCT05720117
NCT06658951
NCT05098132
NCT05719558
NCT05101070
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions